Major surgery within 28 days of starting study treatment and patients must have recovered from any effects of any major surgery
Patients must have fully recovered from any adverse effects of major surgery (to =< grade 1) at least 14 days prior to registration
Major surgery within 2 weeks prior to randomization: patients must have recovered from any effects of any major surgery
Major surgery must not have occurred within 2 weeks prior to enrollment and patients must have recovered from any effects of any major surgery
Patient has had major surgery within 14 days prior to treatment start or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Major surgery =< 14 days prior to registration or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
?4 weeks since any major surgery and fully recovered.
Participants who have had major surgery within 2 weeks prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 3 weeks prior to first dose of study treatment, and patients must have recovered from the effects of surgery
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Subjects must have recovered from major side effects of prior therapies or procedures.
Participants who have undergone major surgery within 14 days of starting the study treatment, or participants who have not recovered to baseline status from the effects of major surgery received more than 14 days prior.
Has not fully recovered from any effects of major surgery without significant detectable infection.
Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery
Prior major surgery within 12 weeks or prior major surgery from which the patient has not sufficiently recovered yet
PHASE II EXCLUSION CRITERIA: Prior major surgery within 12 weeks or prior major surgery from which the patient has not sufficiently recovered yet
Major surgery within 2 weeks of starting the study treatment, or not recovered to baseline status from the effects of surgery received > 2 weeks prior
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Participants who have undergone major surgery within 14 days of starting the study treatment, or participants who have not recovered to baseline status from the effects of major surgery received more than 14 days prior
Major thoracic or abdominal surgery from which the patient has not sufficiently recovered yet
Have had major surgery other than a minor outpatient procedure within 4 weeks prior to dose assignment or have not recovered from major side effects of the surgery if more than 4 weeks have elapsed since surgery
Fully recovered from any effects of major surgery, and be free of significant infection
Patients who have had major surgery must be fully recovered and >= 4 weeks post-operative prior to enrolling on study
Patients that have had major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 2 weeks of starting study treatment and subjects must have recovered from any effects of any major surgery.
Major surgery within 28 days prior to starting study drug or has not recovered from major side effects of the surgery.
Major surgery =< 14 days prior to starting study treatment or who have not recovered from side effects to < grade 2 CTCAE
Recent major surgery within 4 weeks prior to starting study treatment. Minor surgery within 2 weeks of starting study treatment. Patients must be recovered from effects of surgery
Subject has had major surgery within 14 days prior to registration or has not recovered from major side effects of the surgery (tumor biopsy is not considered as major surgery).
Patient has had major surgery (e.g., intra­thoracic, intra­abdominal or intra­pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video­-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these procedures
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Subject who has not recovered from the effects of any major surgery prior to initial treatment
Surgery: at least 2 weeks since undergoing any major surgery and must be recovered from effects of surgery
Major surgery within 14 days of registration and patients must have recovered from any effects of any major surgery
Major surgery within 14 days prior to starting study drug or has not recovered from surgical complications (tumor biopsy is not considered as major surgery)
Had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgery
Patients who have had major surgery must be fully recovered and require a recovery period of >= 4 weeks prior to enrolling on study
Has had any major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgery
Any major surgery (within 4 weeks of Study Day 1, or has not recovered from the effects of such surgery).
Major thoracic or abdominal surgery from which the patient has not sufficiently recovered yet
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (all surgical wounds must be fully healed); for the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia (tumor biopsy is not considered as major surgery)
The patient is not recovered from minor or major surgery and is less than 4 weeks from major surgery prior to starting treatment with pembrolizumab
Major surgery =< 14 days prior to registration or have not recovered from side effects of such therapy
Major surgery, or not recovered from major surgery within 4 weeks before the first dose of study treatment
Major surgery <=4 weeks before the first dose of study treatment. Subjects must have also fully recovered from any surgery (major or minor) and/or its complications before initiating study treatment.
Have had major surgery ? 2 weeks prior to starting treatment with Andes-1537 or who have not recovered from side effects of such surgery
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Major surgery or radiation ? 2 weeks prior to starting study treatment or who have not recovered from side effects of surgery or radiation
At least 4 weeks have elapsed since the completion of major surgery, and the patient has fully recovered from this surgery and any post-surgical complications
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
Patient who has undergone major surgery =< 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure; note: core needle biopsy, diagnostic tonsillectomy or excisional lymph node biopsy do not constitute major surgery
Patients must be at least 4 weeks (28 days) from major surgery and fully recovered from all acute effects of prior surgical intervention
Major thoracic or abdominal surgery from which the patient has not yet recovered.
Patients who have had major surgery or trauma within 28 days prior to entering the study; patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment
Major surgery =< 4 weeks prior to registration or have not recovered from side effects of such therapy
Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 2 weeks of first dose of study drug; patients must have recovered from the effects of any surgery performed greater than 2 weeks previously
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 2 weeks of first dose of study drug; patients must have recovered from the effects of any surgery performed greater than 2 weeks prior
Subject has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Patients may have received prior surgery; for all major surgeries, at least 14 days must have elapsed since completion and patient must have recovered from all major side effects of surgery per investigator’s assessment
PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have had a major surgery within 28 days prior to registration; patients must have recovered from any adverse effects of prior surgery to the satisfaction of the treating physician; biopsies and central IV access placement are not considered major surgery
Subject has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects
Major surgery within 2 weeks prior to registration; patients must have recovered from any effects of any major surgery
Patient has had major surgery =< 14 days prior to registration or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Are at least 4 weeks from major surgery and recovered.
Major surgery ? 2 weeks prior to starting study drug or still recovering from post operative side effects.
Patients must be at least 4 weeks from major surgery and must be fully recovered
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered a major surgery)
Major surgery ? 2 weeks and recovered from any clinically significant effects of recent surgery.
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery).
Major surgery within 2 weeks of first dose of study drug; patients must have recovered from the effects of any surgery performed greater than 2 weeks previously
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery =< 4 weeks prior to starting study regimen or who have not recovered from surgery
Patient underwent major systemic surgery =< 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery
Surgery: at least 2 weeks since undergoing any major surgery and must be recovered from effects of surgery
Major thoracic or abdominal surgery from which the patient has not yet recovered.
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
Major surgery within 2 weeks of study treatment initiation and patients must have recovered from any effects of any major surgery.
Patients who have not recovered from the side effects of any major surgery
Major surgery =< 4 weeks prior to registration or have not recovered from side effects of such therapy
Major surgery within 2 weeks of starting study treatment, and subjects must have recovered from any effects of any major surgery;
Patients who have had major surgery must be fully recovered and >= 4 weeks post-operative prior to enrolling on study
Major surgery within 6 weeks prior to Baseline. The subject must have recovered from surgery and be without current complications of infection or dehiscence.
Patient had major surgery within 28 days prior to starting study drug or has not recovered from major side effects of the surgery
Major surgery within 2 weeks of first dose of study drug. Patients must have recovered from the effects of any surgery performed greater than 2 weeks previously.
At least 4 weeks have elapsed since the completion of major surgery, and the patient has fully recovered from this surgery and any post-surgical complications.
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
Major surgery ? 2 weeks or radiotherapy ? 4 weeks prior to planned start of study drug or patient has not recovered from major side effects.
Patients must be at least 4 weeks from major surgery and have fully recovered from any effects of surgery, and be free of significant detectable infection prior to registration
Major surgery within 14 days prior to starting Investigational Product or has not recovered from major side effects.
Prior major surgery from which the subject has not yet recovered to baseline;
Patients must have fully recovered from any effects of major surgery, and be free of significant detectable infection
Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery
Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery
Patients must be at least 4 weeks from major surgery and have fully recovered from any effects of surgery, and be free of significant detectable infection
If a patient has had major surgery, the patient must be longer than four weeks post surgery and must have recovered from all toxicity prior to beginning protocol study
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects
Has not recovered from major surgery prior to starting study therapy
>= 4 weeks since last major surgery and fully recovered
Recovered from major surgery within the last 6 months
Major surgery within 1 month of starting study program and patients must have recovered from any effects of major surgery
The patient must be recovered from a prior major surgery; the major surgery must be performed at least 4 weeks prior to consent date
Patient underwent major systemic surgery =< 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drug
Major surgery within two weeks of study registration of which the patient has not recovered
Participants with acute intercurrent illness or those who had major surgery within the preceding 4 weeks unless they have fully recovered
Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery
Patients who have undergone major surgery (ie, intra-thoracic, intra abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of previous procedure or injury
Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting INC280 or who have not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure
Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures (i.e. TURBT), percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Prior intra-abdominal surgery within 4 weeks of trial enrollment.
Patients who have had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 2 weeks prior to starting study drug or who have not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure
Patients who have undergone major surgery (e.g. intra-thoracic, intra- abdominal or intra-pelvic), open biopsy or significant traumatic injury ? 4 weeks prior to starting study drug, or patients who have had minor procedures (i.e. transurethral resection of bladder tumor [TURBT]), percutaneous biopsies or placement of vascular access device ? 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Major surgery (e.g. intra-abdominal, intra-thoracic or intra-pelvic) within 4 weeks prior to starting study treatment or lack of recovery from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these procedures
CERITINIB EXCLUSION CRITERIA: Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting capmatinib; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure
Patient has had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these procedures
Patient has had major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these procedures
Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Minimum interval since last major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy, or significant traumatic injury is 4 weeks prior to registration; minimum interval since minor procedures, percutaneous biopsies or placement of vascular access device is 1 week prior to registration; patients must have recovered from side effects of such procedure or injury prior to registration
SUB-PROTOCOL AIM A: Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) =< 4 weeks prior to registration or failure to recover from side effects of such surgery; exceptions: port placements, nephrectomy, tumor biopsies, and minor surgeries
Any surgery that is potentially hemorrhagic (e.g. intra-thoracic, intra-abdominal or non-traumatic orthopedic surgery of the femur or pelvis) that is completed within 12 hours prior to first dose of study drug, or ongoing impairment of hemostasis as a result of one of these procedures
Patients within 28 days post major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic), open biopsy, or significant traumatic injury to avoid wound healing complications; minor procedures and percutaneous biopsies or placement of vascular access device without complications require 48 hours prior to study entry
Prior systemic therapy, radiation therapy or intracavitary surgery (intra-thoracic, intra-abdominal or intracranial) within 28 days of starting study treatment
Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks and minor procedures (including percutaneous biopsies, placement of vascular access device, laparoscopy +/- biopsy) =< 1 week prior to starting study treatment; patients who have minor procedure(s) > 1 week prior to starting study treatment and have recovered from side effects of such procedure are eligible
Patient has had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these procedures
Undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 28 days prior to study registration, or had minor procedures, percutaneous biopsies or placement of vascular access device =< 7 days prior to study registration, or have not recovered from side effects of such procedure or injury
Major surgery such as intra-thoracic, intra-abdominal or intra-pelvic (with the exception of craniotomy), open biopsy or significant traumatic injury ? 4 weeks prior to registration, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device ? 1 week prior to registration, or who have not recovered from side effects of such procedure or injury.
Participants who have received systemic chemotherapy within 3 weeks of starting study drug
Participants who have received radiation therapy within 2 weeks of starting study drug; Note: participants who have received radiation therapy to a small volume (e.g. stereotactic radiosurgery to the CNS) will be eligible if completed > 1 week prior to starting study drug
Radiation therapy, chemotherapy, and other investigational agents within 3 weeks (6 weeks for nitrosourea or mitomycin C) prior to starting fenretinide + safingol; patients must have recovered from toxicities of prior therapy
Patients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies =< 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
Chemotherapy within 3 weeks of starting study drug (6 weeks if prior nitrosourea)
Patients who have received chemotherapy or any investigational drug < 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patient is currently receiving or has received systemic corticosteroids (=< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment)
Chemotherapy or radiotherapy within 14 days prior to starting study treatment; in case of monoclonal antibodies/biologics, within 28 days prior to starting study treatment
Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy; guidelines for this recovery period are dependent upon the specific therapeutic agent being used:\r\n* Patients who are less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 consecutive scans with disease progression or histopathologic confirmation of recurrent tumor\r\n* Patients who have received chemotherapy or bevacizumab =< 4 weeks (except for nitrosourea [6 weeks] or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide [1 week]) prior to starting the study drug unless patients have recovered from side effects of such therapy\r\n* Patients who have received immunotherapy =< 4 weeks prior to starting the study drug unless patients have recovered from side effects of such therapy
Patients may not have received chemotherapy or bevacizumab =< 4 weeks (except for nitrosourea [6 weeks] or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide [1 week]) prior to starting the study drug unless patients have recovered from side effects of such therapy
Patients may not have received immunotherapy =< 4 weeks prior to starting the study drug unless patients have recovered from side effects of such therapy
Patient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment
Currently receiving or has received systemic corticosteroids within 4 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment (steroids for endocrine replacement is allowed)
Patients who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies ? 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
Patients who have received either immunotherapy within =< 8 weeks; chemotherapy within =< 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Treatment with any of the following anti-cancer therapies prior to the first dose of BGJ398 within the stated timeframes\r\n* Cyclical chemotherapy (intravenous) within a period of 2 weeks unless there are ongoing side effects > grade 2\r\n* Biological therapy (including small molecules, and/or) within a period of time that is =< 2 weeks prior to starting study drug unless there are ongoing side effects > grade 2\r\n* Any other investigational agents within a period =< 2 weeks prior to starting study drug unless there are ongoing side effects > grade 2\r\n* Wide field radiotherapy (including radioisotopes) =< 2 weeks prior to starting study drug unless there are ongoing side effects > grade 2
Subjects must have completed their most recent drug therapy directed at multiple myeloma in the following timeframes: \r\n* Chemotherapy, biological therapy, immunotherapy, or an investigational therapy at least 2 weeks prior to starting DS3032b\r\n* Corticosteroids at least 2 weeks prior to starting DS3032b, except for a dose equivalent to dexamethasone of >= 4 mg/day\r\n* Nitrosoureas, nitrogen mustards, mitomycin C, or monoclonal antibodies at least 6 weeks prior to starting DS3032b\r\n* Autologous stem cell transplantation at least 12 weeks prior to starting DS3032b\r\n* Allogeneic stem cell transplantation at least 24 weeks prior to starting DS3032b, and these subjects must also NOT have moderate to severe active acute or chronic graft versus host disease (GVHD)\r\n* Previous and concurrent use of hormone replacement therapy, the use of gonadotropin-releasing hormone modulators for prostate cancer, and the use of somatostatin analogs for neuroendocrine tumors are permitted if such therapy has not been changed within 8 weeks before study drug treatment
Having received immunotherapy or chemotherapy within 2 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =< 5 effective half-lives prior to registration or who have not recovered from side effects of such therapy
Patients who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosourea, mitomycin-C, targeted therapy and radiation) =< 4 weeks prior to starting study drug
Patients who have received the last administration of nitrosourea or mitomycin-C =< 6 weeks prior to starting study drug
Patients who have received targeted therapy (e.g., sunitinib, sorafenib, pazopanib), except ALK inhibitors, =< 2 weeks prior to starting study drug
Recent history of allergen desensitization therapy within 4 weeks of starting study treatment.
Patients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug; all side effects from prior therapy must recover to grade 1 or less prior to starting on trial
Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =< 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy
-  Subjects who have received any prior chemotherapy, radiotherapy, biologic/targeted\n             anti-cancer therapy or surgery within 4 weeks (6 weeks for monoclonal antibodies,\n             radioactive monoclonal antibodies or any radio- or toxin- immunoconjugates) before\n             the first study drug administration and have not recovered (to AEs <  Grade 2) from\n             the toxic effects from any prior therapy
Patient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment
Subject is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug or who have not fully recovered from side effects of such treatment
Prior treatment with any cytotoxic chemotherapy except as an adjuvant therapy; patient should not have received gemcitabine within 6 months of starting the study treatment; 5-flourouracil or radiation treatment should be received more than 4 weeks prior to receiving the study drug
Patients who have received radiation therapy to more than half of the pelvis or more than half of the spine within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Patients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =< 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy
Patient has received chemotherapy, targeted anticancer therapy, pelvic and/or para-aortic radiotherapy or has had major surgery =< 4 weeks (6 weeks for nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy
Survival expectation of 12 weeks or longer after starting study drug
Patient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment
Patient has received chemotherapy or targeted anticancer therapy, monoclonal antibodies =< 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C prior to starting the study drug, or the patient has not recovered side the side effects of such therapy
Patients who have received prior systemic anti-cancer treatment, such as cyclical chemotherapy or biological therapy within a period of time that is shorter than the cycle length used for that treatment (e.g. 6 weeks for nitrosourea, mitomycin-C) prior to starting study treatment
Patients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade 1 before starting the trial
Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =< 5 effective half-lives prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have received chemotherapy or radiation therapy to > 30% of marrow bearing bone within < 2 weeks or experimental agent/therapy within 4 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Patients who have received oral or IV chemotherapy, targeted anticancer therapy or radiation therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to study enrollment
Patient was treated with trastuzumab or other antibody based therapy within three weeks of starting study treatment or with chemotherapy or hormonal cancer therapy within two weeks of starting study treatment.
Survival expectation of 12 weeks or longer after starting study drug.
Patients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade 1 before starting the trial
Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =< 2 weeks (or =< 3 weeks for a monoclonal antibody) prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have received either immunotherapy within =< 8 weeks; chemotherapy within =< 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Patients who have received chemotherapy within </= 2 weeks by time of cycle 1 day 1 of therapy on trial ; or radiation therapy to > 30% of marrow-bearing bone within 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies.
Patients who are newly diagnosed should have not received any other chemotherapeutic therapy (with the exception of dexamethasone) 1 week before starting, or radiation therapy, 4 weeks before starting
Patients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade 1 before starting the trial
Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =< 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =< 5 effective half-lives prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C, and 1 week for hormone therapy) prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have received systemic steroids within 4 weeks prior to starting study treatment
Prior local therapy within 2 weeks of starting the study treatment
Patients who have received either immunotherapy within =< 8 weeks; chemotherapy within =< 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Patient has received chemotherapy or anticancer therapy ? 4 weeks prior to starting study drug
Patient has received chemotherapy or anticancer therapy ? 4 weeks (6 weeks for nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug.
Patients who have received prior systemic anti-cancer treatment, such as cyclical chemotherapy or biological therapy within a period of time that is shorter than the cycle length used for that treatment (e.g. 6 weeks for nitrosourea, mitomycin-C) prior to starting study treatment.
Chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug
Any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =< 5 effective half-lives prior to starting study drug or patients who have not recovered from side effects of such therapy
Patients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosourea, mitomycin-C, targeted therapy and radiation) =< 3 weeks prior to starting study drug, or who have side effects (except alopecia, lymphopenia and hyperglycemia) that have not resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less
Patients who have received the last administration of nitrosourea or mitomycin-C =< 6 weeks prior to starting study drug, or who have side effects (except alopecia, lymphopenia and hyperglycemia) that have not resolved to NCI CTCAE grade 1or less
Patients who have received targeted therapy (e.g. sunitinib, sorafenib, pazopanib) =< 1 week prior to starting study drug, or who have not recovered from the side effects of such therapy
Patients who have received either immunotherapy within =< 8 weeks; chemotherapy within =< 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Patients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy (except alopecia)
Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =< 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy (except alopecia)
Patients treated with chemotherapy or biologic therapy or other investigational agent < 2 weeks prior to starting study drug for compounds with a half-life ? 3 days, and < 4 weeks prior to starting study drug for compounds with a prolonged half-life were excluded.
Patients who have received either immunotherapy within =< 8 weeks; chemotherapy within =< 3 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
patients who received dasatinib within 3 days of starting study drug
patients who received imatinib within 5 days of starting study drug
All patients must be off previous chemo- and/or radiotherapy for at least three (3) weeks prior to entrance into the study and have recovered from any toxic effects induced by such treatment(s). Patients who have received a nitrosourea type drug must have had no treatment within the last six weeks.
Received the last administration of nitrosourea or mitomycin-C =< 42 days prior to study registration, or who have not recovered from the side effects of such therapy
Previous treatment with immunotherapy within 8 weeks of starting study medication, chemotherapy, radiotherapy, molecular-targeted therapy, or biological therapies (including HER2 directed therapies) within 4 weeks of starting study medication, or hormone therapy within 2 weeks of starting study medication.
Recent history of allergen desensitization therapy within 4 weeks of starting study treatment.
Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy =< 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C prior to starting the study drug, or the patient has not recovered from the side effects of such therapy
Patients who have received prior systemic anticancer therapy ? 3 weeks prior to study start (6 weeks for nitrosourea, antibodies, or mitomycin-C)
Planned surgery or radiation therapy during protocol treatment
Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
Major surgery, radiation therapy, or systemic anti-cancer therapy within 28 days of starting study treatment.
Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study treatment
Major surgery within 28 days of starting study treatment; -or- systemic anti-cancer therapy within the lesser of 28 days or 5 half-lives of the prior therapy before starting study treatment -or- recent radiation therapy with unresolved toxicity.
Major surgery, radiation therapy or systemic anti-cancer therapy within 2 weeks of starting study treatment
Major surgery, radiation, or treatment with any other investigational drug within 2 weeks of study treatment
May have received prior radiation therapy or surgery; however, at least 21 days must have elapsed since completion of radiation therapy or surgery and subject must have recovered from all side effects at the time of registration
Pre-planned concurrent cytotoxic chemotherapy, surgery, or radiation therapy during protocol treatment; radiation therapy is not permitted while on study
Patients must have undergone radiation therapy and surgery as part of their standard of care\r\n* Stratum A: Radiation therapy must have started within 4 weeks of diagnosis by imaging or surgery, whichever is later\r\n* Stratum B: For subjects undergoing surgery for more extensive resection, radiation therapy should be started within 4-6 weeks from surgery\r\n* H3.3K27 mutation must have been confirmed in the tumor tissue in a CLIA approved laboratory
Patient must have had previous treatment with definitive surgery or radiation therapy or cryoablation
All previous cancer therapy including radiation, chemotherapy, and surgery, must have been discontinued at least 4 weeks prior to treatment in this study
Patients who have received radiation therapy, radionuclide therapy or undergone major surgery within 4 weeks of enrollment; a biopsy will not preclude a patient from starting study
PRIOR THERAPY OR SURGERY
Patients who have received radiation therapy, radionuclide therapy or undergone surgery within certain duration (4 weeks) of enrollment
Must be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment
Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry
Must be recovered from any reversible side effects of prior therapy (e.g. no major surgery, no antineoplastic or experimental therapy, or no significant radiation therapy to hematopoietic sites within 4 weeks of Baseline/C1D1, and no nitrosoureas or nitrogen mustards within 6 weeks of Baseline/C1D1)
At least 2 weeks beyond prior treatment (chemotherapy, investigational drugs including small molecular inhibitors, endocrine therapy, immunotherapy and/or radiation therapy) or major surgery, and recovered from all acute toxicities to Grade 1 or less (except alopecia and peripheral neuropathy).
Patients may have received prior radiation therapy or surgery; however, at least 14 days must have elapsed since completion of radiation therapy or surgery and patient must have recovered from all side effects at the time of registration (e.g. back to baseline or grade 1)
Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within four weeks prior to study entry
Patients who have received radiation therapy, major surgery, other locoregional therapy, within 4 weeks prior to the first date of SBRT
Treatment with radiation therapy, surgery, or investigational therapy within one month prior to registration
Must be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, and 8 weeks since any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment
Previous treatment with surgery, radiation, chemotherapy, targeted agents are allowed provided that: \r\n* Chemotherapy/major surgery was administered > 14 days before the start nivolumab\r\n* Minor surgery, radiation, or any targeted agents were administered > 7 days before the start of nivolumab
Patients must have recovered to less than grade 1 or to baseline from toxicity of prior chemotherapy or biologic therapy and must not have had major surgery, chemotherapy, radiation or biologic therapy within 2 weeks prior to beginning treatment; NOTE: Exceptions to this include events not considered to place the subject at unacceptable risk of participation in the opinion of the principal investigator (PI) (e.g., alopecia)
A minimum time period must elapse between the end of a previous treatment and start of study therapy:\r\n* 1 week from the completion of radiation therapy for brain metastases\r\n* 4 weeks from the completion of chemotherapy or any experimental therapy\r\n* 4 weeks from prior major surgery (such as open biopsy or significant traumatic injury)
Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 2 weeks before randomization; Note: no washout required for single dose Gamma Knife radiation
Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of starting study treatment, depending on the patient cohort
Must not have had major surgery or radiation therapy within 14 days of starting study treatment
Subjects who have received radiation therapy, major surgery, other locoregional therapy, within 4 weeks prior to the first dose of study drug
Radiation therapy must begin within 12 weeks of surgery
Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit.
> 4 weeks since prior radiation, surgery or chemotherapy
Patients who will receive radiation therapy as their primary treatment after surgery
At least 4 weeks post-surgery, and must be at least 3 months post-radiation therapy, with resolution of related toxicities
Surgery or radiation planned within 8 weeks of starting therapy
Previous treatment with surgery, radiation or hormonal therapy is allowed
Patients must be >= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >= 5 half-lives or >= 3 weeks from the last dose (whichever comes first); patients previously treated with vemurafenib monotherapy do not have to stop medication before they start on the protocol
Participants may have had any extent of prior surgery and/or chemotherapy; no prior cranial radiation therapy is allowed
> 4 weeks since prior radiation, surgery or chemotherapy
Patients must be at least 2 weeks from prior systemic therapy, radiation therapy, major surgery, or other investigational therapy, and have recovered from clinically significant toxicities of these prior treatments
Prior systemic chemotherapy, major surgery, or thoracic radiation within 3 weeks of study initiation.
Requirement for other forms of anticancer treatment while on trial, including maintenance therapy, other radiation therapy, and/or surgery.
Prior chemotherapy, immunotherapy, radiotherapy or major surgery (including radiation therapy or surgery for treatment of brain metastases) must be completed at least 3 weeks before study entry; prior PD-1 or PD-L1 therapy is acceptable
At least 4 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities.
At least 4 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities
Patients must be at least 2 weeks from major surgery, radiation therapy, participation in other investigational trials and must have recovered from clinically significant toxicities of these prior treatments
At least a 12 week interval should have elapsed between prior surgery, radiation therapy, chemotherapy or any other treatment and the first vaccination; patients should have recovered from surgery and adjuvant treatment
At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment
Prior surgery and chemotherapy allowed, no prior radiation to the target area (breast or chest and nodes); NOTE: Radiation should occur 3-12 weeks after last chemotherapy or surgery, whichever comes last
Patients must be at least 4 weeks from radiation therapy or major surgery and have recovered from prior toxicities
Patients with intracranial metastases, which have been treated by surgery or radiation therapy, may be eligible for study provided there is no evidence of active disease and no requirement for anticonvulsant therapy or steroids following treatment
Prior major surgery or radiation therapy within 14 days of initiation of treatment
At least 12 weeks beyond stem cell transplant and 4 weeks beyond chemotherapy or\n             immunotherapy, major surgery, other experimental treatments, or radiation therapy to\n             the index lesions, and with all acute toxicities from prior therapy resolved to less\n             than Grade 2 toxicity by NCI CTC version 4.0
Subjects must have recovered from the acute side effects of any prior surgery, chemotherapy, or radiation therapy; a minimum time period at least 6 months should have elapsed from prior radiation treatment until enrollment in the study
Major surgery or radiation therapy < 4 weeks of starting study treatment
Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 28 days prior to study entry.
Time elapsed from previous therapy must be ? 3 weeks for systemic therapy, ? 2 weeks for radiation therapy or major surgery.
Has had major surgery within 4 weeks, received radiation therapy within 2 weeks prior to randomization, or has not recovered (i.e., ? Grade 1 or at baseline) from AEs due to prior treatment.
Prior Therapy • Patients must have not received any prior therapy other than surgery, radiation and/or steroids.
Prior systemic therapy, radiation therapy, or surgery within 28 days of starting study treatment
Patients must be >/= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. Patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol. For biologic/targeted agents patients must be >/= 5 half-lives or >/= 3 weeks form the last dose (whichever comes first).
Patients with locoregional disease that have not received appropriate standard locoregional therapy with surgery and/or radiation therapy
Patients must not have received chemotherapy, radiation therapy, or undergone major surgery within 4 weeks prior to enrollment
The patient has received chemotherapy, surgery, or radiotherapy (for therapeutic purposes) within 3 weeks of initiating study treatment (4 weeks for bevacizumab or investigational drugs) or the patient has not recovered (grade >= 2 from side effects of the previous therapy); patients who receive palliative radiation therapy can be treated immediately after completion of radiation therapy
Subjects must not have had prior surgery (biopsy allowed) or radiation therapy within 6 months of enrollment.
Prior intraabdominal, intrathoracic, vascular, spinal or intracranial surgery or radiation therapy within 4 weeks of starting treatment
Patients may have received prior radiation therapy or surgery; however, at least 14 days must have elapsed since completion of radiation therapy or surgery and patient must have only grade 2 or less adverse effects at the time of registration
Brain metastases unless documented to be controlled post completion of local therapy (surgery and/or radiation therapy) for at least four weeks prior to registration
Treatment with any of the following anti-cancer therapies:\r\n* Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of study treatment
For radiation required prior to surgery, the participant must register within 84 days of surgery. Also, participants in this situation would not be required to have additional post-mastectomy radiation therapy.
HNSCC and cSCC cannot be curable by surgery and/or radiation therapy
Patients who have received radiation therapy, radionuclide therapy or undergone surgery within certain duration (4 weeks) of enrollment
Patients must be at least 2 weeks from major surgery, radiation therapy, participation in other investigational trials and must have recovered from clinically significant toxicities of these prior treatments
Patients who have had major surgery or radiation therapy within 21 days of starting treatment
Patients must have recovered from prior treatment regimens, e.g. surgery, radiation
Major surgery or radiation therapy within four weeks of the first dose of ARQ 087
Patients must be >= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; a confirmation (written or verbal) that there is no risk of surgical complications from a patient’s surgeon has to be obtained prior to starting therapy in patients with a history of major surgery within past 6 weeks; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >= 5 half-lives or >= 3 weeks form the last dose (whichever comes first)
Patient must not have had radiation therapy, minor surgery, or tumor embolization with 14 days prior to the first dose of pazopanib
Patients must not have received chemotherapy, radiation therapy, or undergone major surgery within 4 weeks prior to enrollment
Major surgery or radiation therapy < 4 weeks of starting study treatment
Patients may have received prior radiation therapy or surgery; however, at least 21 days must have elapsed since completion of radiation therapy or surgery and patient must have recovered from all side effects at the time of registration
Prior treatment (major surgery, radiation therapy, chemotherapy, or other investigational drugs) received within 28 days before randomization.
Major surgery or radiation treatment < 4 weeks prior to enrollment; in addition, cannot have received radiation to the thorax or gastrointestinal tract within three months of the first dose of study treatment
Patients will be ineligible if surgery and chemotherapy was completed >= 20 weeks from the planned start date of radiation therapy or if the patient is referred for radiation therapy after a relapse of prior ipsilateral breast cancer; surgery can exceed 20 weeks if the patient undergoes chemotherapy following surgery
Major surgical procedure or any radiation therapy within 4 weeks of treatment, minimum rest period is 28 days post surgery; maximum rest period 56 days post surgery
Minimum of four weeks since any major surgery or since completion of radiation (patients should have adequately recovered from the acute toxicities of any prior therapy)
Patients must be >= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >= 5 half-lives or >= 3 weeks form the last dose (whichever comes first)
All previous therapy not associated with peripheral blood stem cell transplant, including radiation, hormonal therapy, and surgery, must have been discontinued 4 weeks prior to treatment in this study
Major surgery, locoregional therapy, or radiation therapy within four weeks of the first dose of ARQ 087
Previous treatment with definitive surgery or radiation therapy or both
Major surgery, chemotherapy, radiation therapy or other cancer therapy within 3 weeks of treatment day 1
Must be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, and 8 weeks since any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment
Radiation therapy or surgery in the past 4 weeks
Patient with major surgery or radiotherapy within 4 weeks prior to the start of the study treatment (i.e., D1 of Cycle 1). Prior surgery or radiation therapy aimed at local palliation or attempted local disease control is permitted
TREATMENT: Patients with no more than 3 intracranial metastases, which have been definitively treated by surgery or radiation therapy may be eligible for the study, provided there is no evidence of active disease for at least 2 months and no requirement for anticonvulsant therapy or steroids following treatment
Prior treatment including surgery, chemotherapy or radiation therapy for the current primary breast cancer
Radiation and surgery within 4 weeks prior to treatment in this study
Patients in whom surgery or radiation therapy may be impractical
have stable neurologic status post administration of local therapy (surgery or radiation) for a minimum of 2 weeks following completion of the definitive therapy.
Any site of disease that is not amenable to definitively local therapy including surgery or radiation therapy
Any medical co-morbidities that would preclude surgery or radiation therapy
Must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy AND
Recovered from prior radiation therapy or surgery
Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatment
Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
Cancer progression after treatment with the following: surgery, radiation therapy and temozolomide as first line treatment with no other therapy prior to tumor recurrence.
Subjects who received any of the following within the last 14 days of initiation of study treatment: 1) Plasmapheresis, 2) Major surgery, 3) Radiation therapy, 4) Use of any anti-myeloma drug therapy
initial definitive therapy such as surgery with or without adjuvant radiation
Patients with intracranial metastases, which have been treated by surgery or radiation therapy, may be eligible for study provided there is no evidence of active disease and no requirement for anticonvulsant therapy or steroids following treatment
Have received surgery, chemotherapy, and/or radiation therapy
For stage I-III disease, patients should be 2-24 months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the 12-week study and no evidence of disease
Have not completed surgery, chemotherapy, or radiation treatment associated with their diagnosis; a washout period of a minimum of 6 weeks is required from the last anti-cancer treatment received except hormonal therapy
Definitive radiation treatment with or without concurrent chemotherapy with curative intent; treatment prior to radiation therapy is acceptable (e.g. surgery, chemotherapy)
Completion of treatment (e.g., chemotherapy, radiation therapy, surgery, etc.) for gynecologic or breast cancer 6 months or greater in the past
2 months – 10 years status post surgery, radiation and chemotherapy
Planned radiation therapy or surgery to the bone (does not include procedures performed before randomization)
Prior surgery or radiation therapy to the region of interest
Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period; hormonal therapy is allowed
Have undergone some type or combination of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer
Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period; hormonal therapy is allowed
Major surgery or radiation treatment within 3 months
At least 2 weeks since prior chemotherapy, radiation treatment and/or surgery
Patients may have received prior radiation therapy or major surgery; however, at least 21 days prior to treatment start must have elapsed since completion of radiation therapy or major surgery and patient must have recovered from all side effects at the time of randomization
Minimum 3-week interval from last chemotherapy administration and last breast surgery to radiation
Complete response by PET achieved with pre-radiation therapy treatment (surgery or chemotherapy)
Will undergo surgery or chemo-radiation treatment
Complete response by PET achieved with pre-radiation therapy treatment (surgery or chemotherapy)
Has had chemotherapy, radiation, biological cancer therapy or major surgery within 4 weeks prior to the first dose of study treatment
Previous treatment (chemotherapy, radiation, or surgery) to both breasts, including hormone therapy
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days prior to screening; no major surgery, other than diagnostic surgery, is allowed within 4 weeks prior to treatment in the study
Major surgery or significant traumatic injury within 14 days prior to therapy
Major surgery or significant traumatic injury <28 days prior to the first RO6874281 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Participant has not fully recovered from major surgery or significant traumatic injury prior the first dose of study drug or expects to have major surgery during the study period or within 6 months after the last dose of study drug
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients who have had a major surgery or significant traumatic injury within 2 weeks of start of study drug
Major surgery or significant traumatic injury <28 days prior to Cycle 1 Day 1 (excluding fine needle biopsies) or anticipation of the need for major surgery during study treatment
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery or significant traumatic injury within 60 days prior to enrollment
Patients who have had major surgery or significant traumatic injury within 4 weeks prior to registration, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study
Recovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment; endoscopic debridement of RRP lesions is NOT considered a major surgery
Major surgery or significant traumatic injury less than (<) 28 days prior to the first cergutuzumab amunaleukin infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
=< 28 days before first dose of protocol-indicated treatment:\r\n* Anti-cancer treatment with bevacizumab.\r\n* Major surgery requiring general anesthesia or significant traumatic injury.
Major surgery or significant traumatic injury greater than or equal to 28 days prior to the first LMB-100 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Patients must have fully recovered from the effects of any major surgery or significant traumatic injury within 14 days of course 1 day 1 (C1D1)
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before first treatment
Participants must have recovered from the effects of major surgery requiring general anesthesia or significant traumatic injury at least 14 days before treatment arm assignment
Major surgery or significant traumatic injury within 14 days prior to Cycle 1 Day 1
Patients, who have had a major surgery or significant traumatic injury (injury requiring > 4 weeks [28 days] to heal) within 4 weeks (28 days) of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that are expected to require major surgery, other than cytoreductive nephrectomy +/- retroperitoneal lymph node dissection, during the course of the study.
Subjects who have not recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.
Recovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before registration
Major surgery or significant traumatic injury occurring within 21 days prior to treatment
Patients, who have had a major surgery or significant traumatic injury (injury requiring > 4 weeks [28 days] to heal) within 4 weeks (28 days) of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that are expected to require major surgery during the course of the study
Major surgery or significant traumatic injury =< 28 days prior to the first LMB-100 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Major surgery or significant traumatic injury within 2 weeks of run-in
Major surgery or significant traumatic injury occurring within 21 days prior to treatment
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Failure to recover from major surgery or traumatic injury within 4 weeks or minor surgery within 2 weeks prior to Day 1 of treatment.
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Subjects must have recovered from the effects of major surgery requiring general anesthetic or significant traumatic injury at least 14 days before Study Day 0.
Major surgery within 28 days prior to the first study treatment. Participants must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment
Surgery (including open biopsy), significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during study treatment
Major surgery or significant traumatic injury that is not recovered at least 14 days before the initiation of thoracic radiation therapy
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery or significant traumatic injury within 4 weeks of first study drug
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment.
Patients who have had a major surgery or significant traumatic injury within 4 weeks from day 1 of study drug
Major surgery or significant traumatic injury within 4 weeks prior to study entry.
undergone major surgery or suffered from significant traumatic injury
Major surgery, or significant traumatic injury occurring within 21 days prior to treatment
Major surgery or significant traumatic injury within 8 weeks of first study drug; a core pancreatic or liver biopsy does not preclude the patient from the study
Patients who:\r\n* Have had a major surgery or significant traumatic injury within 4 weeks from day 1 of study drug\r\n* Have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or\r\n* Are anticipated to require major surgery during the course of the study
Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
Fully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatment
Subjects who have not recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment
Major surgery, or significant traumatic injury within 4 weeks prior to study entry
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Major surgery or significant traumatic injury within 4 weeks of first study drug
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug,
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study
Has had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment
Major surgery or traumatic injury within 28 days of randomization
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before enrollment
Major surgery or significant traumatic injury < 28 days prior to the first RO6927005 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Major surgery or significant traumatic injury within 14 days of Cycle 1 Day 1.
History of major surgery or traumatic injury =< 28 days prior to registration or other major anticipated procedures requiring general anesthesia during study participation
Significant traumatic injury or major surgery (major surgery means opening of a body cavity, eg, thoracotomy, laparotomy, laparoscopic organ resection, and major orthopedic procedures, eg, joint replacement, open reduction and internal fixation) within 21 days of scheduled dosing day 1;
Major surgery or significant traumatic injury within 4 weeks of first study treatment from which the subject has not fully recovered
Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Major surgery or significant traumatic injury within 4 weeks of randomization or patients that may require major surgery during the course of the study.
Patients who have had a major surgery of significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients who have not recovered from the side effects of a major surgery or significant traumatic injury or patients that may require major surgery during the course of the study
Full recovery from the effects of any major surgery or significant traumatic injury within 14 days prior to the first dose of study treatment
Major surgery or significant traumatic injury occurring within 4 weeks before randomization
Recovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy prior to registration
Patients who have undergone major surgery =< 4 weeks prior to starting study treatment or who have not recovered from side effects of such procedure
Patients who have undergone major surgery within the 2 weeks prior to starting study treatment or who have not fully recovered from previous surgery
Patients who have undergone surgery =< 3 weeks or who have not recovered from side effects of this procedure prior to receiving study drug
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from the side-effects of surgery
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patient who has undergone major surgery =< 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure
Patients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
Have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients had a major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedure
Patients who have undergone major surgery < 4 weeks of initiation of study medication or who have not recovered from side effects of such procedure
Patients who have undergone major surgery <4 weeks prior to starting study drug.
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery 21 days or less prior to starting study drug or has not recovered from adverse effects from such procedure.
Patients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
Prior major surgery =< 3 weeks before study drug or not recovered from side effects of such procedure
Participants who have undergone major systemic surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 4 weeks prior to starting study treatment or who have not recovered from side effects of such procedure
Patients who have undergone major surgery within 4 weeks prior to starting the study treatment
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 4 weeks prior to starting study treatment, who have not recovered from side effects of such procedure
Major surgery =< 2 weeks prior to starting a study drug or who have not recovered from side effects of such therapy
Patients with major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedure
Patients had a major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedure
Patients who have undergone major surgery =< 4 weeks prior to registration or have not recovered from side effects of such procedure are not eligible for participation
Participants who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of the surgery
Patient who has undergone major surgery =< 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 2 weeks prior to registration to study or who have not recovered from the side-effects of surgery
Patients who have undergone major surgery =< 4 weeks prior to registration or who have not recovered from side effects of such procedure are not eligible for participation
Participants who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of the surgery
Patients who have undergone major surgery =< 4 weeks prior to starting study treatment, who have not recovered from side effects of such procedure
Participants who have undergone any major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Participants who have undergone any major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery or radiotherapy ? 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Have undergone major surgery =< 2 weeks prior to starting BKM120 or BYL719 or have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 4 weeks prior to starting treatment or who have not recovered from side effects of such therapy
Major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery =< 2 weeks prior to starting a study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
Major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery ? 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
A history of gastrointestinal malabsorption or having undergone surgery requiring gastrointestinal anastomoses within four weeks of starting therapy or who have not recovered from major surgery within three weeks of starting therapy
Patients who have undergone any major surgery within 2 weeks prior to starting study drug or who have not adequately recovered from previous surgery
Patients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within two weeks prior to registration for protocol therapy; Note: If the subjects have undergone major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting protocol therapy
Participants must have recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy
Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study allocation. (Notes: Participants must have recovered from all AEs due to previously administered therapies to ? Grade 1 or baseline. If a participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.)
SAFETY RUN-IN: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
RANDOMIZED PHASE II CLINICAL TRIAL: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the participant received major surgery or radiation therapy of >30 Gray units, they must have recovered from the toxicity and/or complications from the intervention
If subject underwent major surgery they must have recovered adequately from the toxicity and/or complications from the procedure prior to starting therapy
Participants who have not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy
If had major surgery, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to study registration
Patients must be adequately recovered from surgery, radiation therapy, or any surgical complications prior to enrollment
Surgery within 4 weeks prior to study registration except for minor procedures. NOTE: Hepatic biliary stent placement is allowed. NOTE: Subject must have adequately recovered from the toxicity and/or complications of major surgery prior to study registration, as determined by the treating physician.
Not recovered from AEs and/or complications from major surgery prior to first dose
Has received prior chemotherapy (including investigational agents) for any malignant disorder, thoracic radiation therapy or prior surgical resection of an esophagogastric tumor\r\n* Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
If received major surgery, not recovered adequately from the toxicity and/or complications from the intervention prior to starting the study
If subjects received major surgery they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting trial therapy
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention and at least two weeks have to pass prior to starting therapy
Have resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the patient received major surgery or radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
Major surgery within 28 days prior to start of study treatment and failure to have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study treatment.
Has had major surgery within 4 weeks or minor surgery within 2 weeks prior to study day 1; subjects must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention per clinical discretion of the investigator prior to starting therapy
Prior major surgery within 2 weeks prior to the first dose of study drug or who has not recovered adequately from the toxicity and/or complications from the intervention
Major surgery =< 28 days prior to registration; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has received locoregional therapy to liver (transarterial chemoembolization (TACE), transarterial embolization (TAE), radiation, radioembolization, or ablation) or surgery to liver or other site within 6 weeks prior to the first dose of study drug; minor surgery must have occurred at least 7 days prior to the first dose of study treatment (cycle 1, day 1); subjects must have recovered adequately (i.e., grade =< 1 or baseline) from the toxicity and/or complications from any intervention prior to starting therapy
Have resolution of toxic effect(s) of the most recent prior chemotherapy to grade 1 or less (except alopecia); if subject received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention
If subject underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
For subject’s who have received major surgery, the subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy
Has undergone major surgery within 3 weeks of Study Day 1, Subject must have recovered adequately from any toxicity and/or complications from the intervention prior to starting therapy;
Has not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy
REGISTRATION TO TREATMENT (STEP 1): Patients who have received major surgery must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
REGISTRATION TO TREATMENT (STEP 2): Patients who have received major surgery must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Received major surgery =< 2 weeks prior to registration, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who received major surgery must be recovered adequately from the toxicity and/or complications from the interventions prior to starting therapy
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment start\r\n* Note: participants must have recovered from all adverse events (AEs) due to previous therapies to =< grade 1 or baseline; participants with =< grade 2 neuropathy may be eligible\r\n* Note: if participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
Has not recovered adequately (i.e., Grade ?1 or baseline) from the toxicity and/or complications from any intervention prior to starting study drug.
Complete resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the subject received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
Has had prior radiation, chemotherapy, targeted therapy, or investigational therapy for cervical cancer\r\n* Note: if subject received major surgery for reason other than cervical cancer, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting treatment
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had major surgery or significant traumatic injury within 4 weeks of study registration. Subjects must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. A diagnostic or research biopsy does not exclude subjects from enrollment. Placement of a vascular access device such as a Port-A-Cath is not considered major surgery
Surgery within 4 weeks prior to study treatment except for minor procedures: NOTES: Hepatic biliary stent placement is allowed. Subject must have adequately recovered from the toxicity and/or complications of major surgery prior to study registration, as determined by the treating physician.
Patient is currently participating in or has participated in a study of an investigational systemic agent to treat MCC; or is using an investigational device within 4 weeks of the first dose of treatment\r\n* NOTE: if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Toxicity from surgery or associated interventions that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parameters
If the patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has undergone major surgery and has not recovered adequately from any toxicity and/or complications from the intervention prior to starting study therapy
Has had major surgery within 3 weeks prior to receiving the first dose of study treatment or has not recovered adequately from toxicity and/or complications from an intervention prior to receiving the first dose of study treatment.
If a subject received major surgery, must have recovered adequately from the toxicity and/or complications from the intervention prior to enrollment.
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior radiation therapy for metastatic melanoma is allowed as long as the patient bears measurable actively growing disease outside the previously irradiated field\r\n* NOTE: if subject received major surgery, they must have recovered adequately from the toxicity (i.e., all symptoms =< grade 1) and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1; Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
The patient has elective or planned major surgery to be performed during the course of the clinical trial
Major surgery within 4 weeks
Have a planned major surgery.
Elective or planned major surgery to be performed during the course of the trial
Major surgery within 3 weeks of scheduled C1D1 dosing.
Recent major surgery within 4 weeks prior to first infusion
Patients who are less than 4 weeks post-op after major surgery
Major surgery within 2 weeks prior to trial entry;
Patients with elective or planned major surgery to be performed during the course of the clinical trial
Has had major surgery in the past 4 weeks.
Major surgery
Major surgery in the last three weeks
At least 2 weeks must have elapsed since undergoing major surgery
Patients who may require major surgery during the course of the study
At least 3 weeks from major surgery
Major surgery or radiation within 4 weeks prior to study entry
Major surgery: 6 weeks
The patient has elective or planned major surgery to be performed during the course of the clinical trial
All major surgery including prior surgery to the brain within 3 weeks of commencement of study therapy
At least 4 weeks since major surgery or radiation therapy
Any major surgery, as determined by the Investigator, within 4 weeks of IMP administration
Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
Major surgery: ?2 weeks
Major surgery ? 2 weeks prior to starting CC-90002.
Patients who have had major surgery within 6 weeks prior to the first dose of study drug or have major surgery planned during the first 12 weeks after MT-3724 has finished.
Major surgery (as defined by the Investigator): ?4 weeks
No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment
Known bleeding risk including serious hemorrhage or hemoptysis within the last 3 months; major surgery within the past 8 weeks or minor surgery within the past 4 weeks
The participant has electively planned or will require major surgery during the course of the study.
Major surgery within 4 weeks before screening
Major surgery within the past 2 months
Have electively planned or will require major surgery during the course of the study.
< 2 weeks since major surgery (i.e., laparotomy or thoracotomy)
Major surgery performed within 4 weeks of study entry
Major surgery, other than diagnostic surgery, occurring 4 weeks prior to study entry; splenectomy will not be considered an exclusionary major surgery
Had major surgery ? 4 weeks of C1D1
Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
Major surgery (major according to the Investigator's assessment) performed within 12 weeks prior to first trial treatment or planned within 12 months after screening, e.g.,hip replacement
Received major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK2879552 administration
Major surgery within prior 4 weeks and minor surgery within 7 days;
Major surgery in the last two weeks of starting study therapy; this does not include procedures like biopsy (needle or excisional) or port placement as these are not considered as major surgery
Major surgery without full recovery or major surgery within 3 weeks of screening
The patient has elective or planned major surgery to be performed during the course of the clinical trial
Major surgery within 3 weeks prior to event 1
CAPMATINIB EXCLUSION CRITERIA: Major surgery (e.g., intrathoracic, intraabdominal or intrapelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting capmatinib; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure
At least 4 weeks from major surgery
Major surgery within 12 weeks of enrolment
Major surgery within 4 weeks of starting study treatment
The patient has elective or planned major surgery to be performed during the course of the clinical trial
Major surgery within 4 weeks of initiation of therapy; clearance letter from primary physician required
Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
Major surgery in the past 4 weeks.
A history of any major surgery within 6 weeks prior to dosing
Any major surgery within the last 3 weeks
Patients who have had major surgery within 4 weeks of initiation of study medication
Major surgery in the past 16 weeks
Major surgery within two weeks prior to trial entry
> 4 weeks since major surgery
>= 2 weeks since major surgery
Major surgery, other than diagnostic surgery, within 2 weeks
Planned major surgery
Major surgery within 4 weeks prior to study treatment.
Major surgery in last 4 weeks, minor surgery in the last 2 weeks
Major surgery within 4 weeks prior to starting INC280
Major surgery/surgical therapy for any cause within 4 weeks of Screening;
Elective or planned major surgery to be performed during the course of the trial
Major surgery within 4 weeks prior to study entry
Any major surgery within the last four weeks.
Has received major surgery within the 4 weeks prior to starting the trial.
Any major surgery within the last four weeks.
Major surgery within the last 4 weeks; minor surgery within the last 2 weeks
Major surgery within 4 weeks prior to inclusion
At least 4 weeks must have elapsed since the last chemotherapy, radiotherapy or major surgery
Major surgery within four weeks before first IMP administration.
Planned major surgery during the study
Patients who are less than 4 weeks post-operative (op) after major surgery
No planned major surgery
Planned major surgery
Major surgery without full recovery or major surgery within 3 weeks of Screening.
Minimum of four weeks since any major surgery, completion of radiation
Patients less than 4 weeks post major surgery
Major surgery, other than diagnostic surgery, occurring 4 weeks prior to study entry; splenectomy will not be considered an exclusionary major surgery
Major surgery within 4 weeks prior to the screening visit
Major surgery within 4 weeks prior to screening.
Participants with major surgery in the 4 weeks prior to randomization (Video-assisted thoracoscopic surgery (VATS) and/or mediastinoscopy is not considered major surgery).
Major surgery for any reason, except diagnostic biopsy, within 4 weeks of enrolment and/or if the subject has not fully recovered from the surgery within 4 weeks of enrolment
Subject has had major surgery, other than diagnostic surgery, within 4 weeks prior to treatment in study.
Major surgery </= 4 weeks before study treatment
Major surgery <4 weeks or radiation therapy <2 weeks of patient registration.
Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
Major surgery for any reason, except diagnostic biopsy, within 4 weeks and/or if the subject has not fully recovered from the surgery within 4 weeks
Major surgery requiring the use of general anesthetic within 4 weeks of study enrollment
Major surgery, other than diagnostic surgery (e.g., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to first dose.
Major surgery without full recovery or major surgery within 3 weeks of Screening.
Major surgery within the previous 4 weeks
Severe infection or major surgery within 4 weeks, or oral or IV antibiotics treatment within 2 weeks prior to enrollment
have an elective or a planned major surgery during the course of the trial
Major surgery within 4 weeks of starting trial
Major surgery
Major surgery within 4 weeks of study treatment
Major surgery within 4 weeks
Received major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK2879552 administration.
Recent major surgery
Major surgery within 4 weeks of study treatment
Have a planned major surgery.
Major surgery, other than diagnostic surgery, within 2 weeks
Major surgery within 4 weeks of starting treatment.
Major surgery within 4 weeks of starting the study treatment
Any major surgery within the last 3 weeks
Major surgery within 4 weeks of initiation of therapy
Major surgery within 4 weeks of initiation of therapy
At least 4 weeks since major unrelated surgery, with full recovery
Major surgery within four weeks before initiation of therapy
No major surgery within 2 weeks of starting study treatment
At least 4 weeks must have elapsed from major surgery
No major surgery within 4 weeks prior to study entry
Any major surgery within the last 4 weeks
Subjects who have had major surgery within 4 weeks prior to entering the study
Patients who are within 4 weeks of major surgery or within 2 weeks of minor surgery
Patients must be > 4 weeks from any major surgery
Major surgery within 4 weeks of random assignment
Major surgery within 4 weeks prior to entering the study
Recovery from any major or minor surgeries; patient must be 4 weeks post-major surgery and 2 weeks post-minor surgery
Major surgery within the last 4 weeks; minor surgery within the last 2 weeks
Major surgery within 4 weeks prior to entering the study
Any major surgery or radiation therapy within four weeks.
Patients that may require major surgery during the course of the study
Major surgery within 4 weeks
>= 2 weeks since major surgery
Major surgery, other than diagnostic surgery, within 2 weeks
Patient has had major surgery within the last 3 weeks
Major surgery within 4 weeks of study randomisation.
At least 4 weeks must have elapsed from major surgery
Any major surgery within 4 weeks of starting treatment on protocol
Recent major surgery (within 4 weeks), other than for diagnosis
Major surgery within 4 weeks (or within 2 weeks following consultation with and approval of Medical Monitor)
Major surgery within 4 weeks of screening
Major surgery or irradiation within two weeks
Major surgery or irradiation within two weeks
Elective or a planned major surgery while on study treatment
Major surgery within 4 weeks prior to entry
The participant has a history of major surgery or treatment other cancer therapy within 2-6 weeks before starting the study
Major surgery within 2 weeks
Major surgery within 4 weeks (less than 28 days) prior to C1D1
Major surgery within 4 weeks prior to C1D1
Major surgery within 4 weeks of C1D1
Major surgery within 4 weeks
Major trauma or surgery w/in prior 4 weeks
Major surgery within the last 2 weeks
Major surgery other than diagnostic surgery =< 4 weeks
At least 3 weeks from major surgery with full recovery
No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment
Major surgery (as judged by the investigator) within 4 weeks
Major surgery or trauma within 4 weeks
Major surgery within 4 weeks prior to IP administration
Subjects may not have any major surgery within 4 weeks
At least 4 weeks from prior major surgery or radiotherapy
Patients who have had major surgery within 4 weeks of initiation of study medication
Has an elective or planned major surgery to be performed during the course of the trial
Elective or a planned major surgery
At least 4 weeks from prior major surgery or radiotherapy.
Radiotherapy or major surgery within 4 weeks
Major surgery within preceding 8 weeks
Major surgery within the past 2 weeks.
Patient is planning major surgery within the next 6 months
Major surgery within 4 weeks or till recovery to baseline functioning (per patient) whichever is shorter
Major surgery within four weeks before consent date
Major surgery within the past 2 weeks
Undergoing major surgery
Patients who have had major surgery within 4 weeks of initiation of study medication
Any major surgery within the last four weeks.
Major surgery within 2 weeks
Major surgery within 4 weeks prior to C1D1.
A minimum of 4 weeks from any major surgery prior to enrollment; coincident standard of care surgery with the research biopsy is permitted during the study
Major surgery within 4 weeks
Major surgery in the past 8 weeks (Arms 1 and 4)
Any chemotherapy within 4 weeks, or major surgery or radiotherapy within the last 14 days.
Major surgery (eg, laparotomy, thoracotomy or joint replacement) within 3 weeks prior to randomization or elective surgery scheduled to be performed during the study.
Patient must have fully recovered from the effects of prior surgery at least 14 days prior to sub-study registration
Patients may have received prior surgery; at least 28 days must have elapsed since surgery and patient must have recovered from any adverse effects of surgery
Surgery (partial or gross total resection or biopsy) must be performed >= 2 weeks prior to registration; patient must have recovered adequately from the effects of surgery
The patient must have recovered from effects of surgery, postoperative infection, and other complications within 28 days prior to step 2 registration
Patient must have recovered from the surgery
Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy
Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy to CTCAE v4.03 grade 1, baseline or less, except for alopecia
Major surgery =< 2 weeks prior to registration or who have not recovered from side effects of such therapy; subjects must have recovered from any effects of recent radiotherapy that might confound the safety evaluation of study drug
Patients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy; they should be free of significant infection
The patient must have recovered from the effects of surgery, postoperative infection and other complications before enrollment;
Patients must be at least 4 weeks from radiation or surgery and recovered from all ill effects
Patients with a recent surgery should have recovered from all effects of the surgery and be cleared by their surgeon
Must have recovered from effects of surgery, postoperative infection and other complications of surgery
Patients must have recovered from the effects of prior therapy
Patients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy
Must have recovered from adverse effects of any prior surgery, radiotherapy or other antineoplastic therapy
Any patient who has had a recent surgery should have recovered from all effects of the surgery and be cleared by their surgeon
Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
Patients must be deemed by the investigators to be fully recovered from both acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy
Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
PHASE I: Recovery from effects of recent surgery, radiotherapy, or chemotherapy must be demonstrated
PHASE II: Recovery from effects of recent surgery, radiotherapy, or chemotherapy must be demonstrated
Not recovered to Grade 1 from adverse effects of prior myeloma therapy or radiotherapy prior to screening.
Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected; the subject should have recovered from the effects of these or of any prior surgery
Recovered from effects of any prior surgery or cancer therapy
Patients must not have chemotherapy, radiotherapy, chemoembolization, radioembolization, or immunoembolization for their malignancy within 30 days prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventions except those listed in Appendix B of the study protocol.
Patients must have recovered from the surgery
Have recovered from the effects of any prior radiotherapy or surgery;
Recovery from the effects of prior therapy:
At least 4 weeks and recovery from effects of prior surgery, prior radiotherapy, or other therapy with an approved or investigational agent
Participant must have recovered from the effects of surgery, postoperative infection, and other complications; has no significant post-operative hemorrhage.
Subjects must have recovered from surgery before study registration
Recovery from effects of recent surgery, radiotherapy, or chemotherapy
Patients must be recovered from both the acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy
Patients must be recovered from both the acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy
Patients must have recovered from effects of recent surgery, radiotherapy or chemotherapy
Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.
Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior system anticancer therapy, radiotherapy or surgery.
Patients must be recovered from effects of recent surgery (28 days must elapse between surgery and the start of treatment with cabozantinib)
Patients with recent resection for recurrent disease must have recovered from the effects of surgery and should not start treatment for at least 28 days after surgery
Patients may have received prior surgery; however, at least 21 days must have elapsed since completion of surgery and the patient must have recovered from all side effects
The patient must have recovered from the effects of surgery, post-operative infection, and other complications before study registration.
Patients who have not recovered from prior surgery
Recovered from effects of recent surgery, radiotherapy, or chemotherapy
Patients must have had no chemotherapy, radiotherapy, or biologic therapy for their malignancy in the month prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventions
Participants must have recovered from the acute effects of chemotherapy and radiotherapy and from surgical side effects following definitive breast surgery.
The patient is, in the investigator's opinion, adequately recovered from the effects of surgery and chemoradiotherapy to participate in this study.
Subjects who have not recovered from the effects of recent surgery
Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy, up to CTCAE grade 1
Patients must be recovered from acute and late effects of any prior surgery, radiotherapy or other anti-neoplastic therapy
Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgery
Recovery from effects of recent surgery, radiotherapy, or chemotherapy
Patients must have recovered from the effects of prior surgery.
Recovered from the effects of any prior systemic therapy, radiotherapy or surgery
Must have recovered from all side effects of their most recent systemic or local treatment
Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.
Recovery from the effects of surgery.
Recovered from effects of recent surgery, radiotherapy, and chemotherapy
Patients must be recovered from the effects of any prior surgery, radiotherapy, or other antineoplastic therapy
Recovered from the effects of prior antineoplastic therapy
Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy. Up to CTCAE Grade 1 is acceptable for patients with known peripheral neuropathy
Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected, but the subject should have recovered from the effects of these or of any prior surgery
Patients having undergone recent resection (within 5 weeks prior to registration) of their glioblastoma to treat current recurrence prior to study treatment must have recovered from the effects of surgery (including patient's skin having fully recovered from the surgical wound) Note: a 4-week window is required after surgery prior to starting treatment. For CNS-related stereotactic biopsies, a minimum of 7 days must have elapsed prior to registration.
Patients must have recovered from prior surgery
Patients must have completed mastectomy or breast-sparing surgery and must have recovered from all side effects of the surgery; if patients were treated with chemotherapy and/or radiation therapy, these treatments must be completed at least 28 days prior to study registration; patients should have recovered from all grade 2 or higher side effects of chemotherapy and/or radiation therapy with the exception of alopecia and peripheral neuropathy; concurrent bisphosphonate and trastuzumab therapies are allowed
Recovered from the effects of any prior surgery or radiotherapy
recovered from any prior surgery